Position in PFE
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$3,706,128
+$3,180,390 QoQ
Shares Held
153,909
+628.9% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.66%
of 13F equity value
Holder Rank
#724
of 2,821 holders
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PFE Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026111 Capital holds $33,935,331 across 7 Drug Manufacturers - General names. PFE ranks #3 (10.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
112,973 | $21,421,940 | |
| 2 | LLY |
ELI LILLY & Co
|
3,764 | $4,514,654 | |
| 3 | PFE |
Pfizer Inc
This page
|
153,909 | $3,706,128 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
15,807 | $1,997,056 | |
| 5 | AMGN |
Amgen Inc
|
3,851 | $1,394,524 | |
| 6 | MRK |
Merck & Co., Inc.
|
4,582 | $588,787 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
5,419 | $312,242 |
All Filings in PFE
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,706,128 | 153,909 | Shares | Sole | 2026-08-05 | |
| 2025-12-31 | $525,738 | 21,114 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $1,337,139 | 52,478 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $975,320 | 40,236 | Shares | Sole | 2025-07-21 | |
| 2025-03-31 | $1,749,549 | 69,043 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $509,004 | 19,186 | Shares | Sole | 2025-03-18 | |
| No filing history on record for this holder in this stock. | ||||||